BRPI0905369A2 - Composição farmacêutica, composição e kit compartimentado - Google Patents
Composição farmacêutica, composição e kit compartimentadoInfo
- Publication number
- BRPI0905369A2 BRPI0905369A2 BRPI0905369-7A BRPI0905369A BRPI0905369A2 BR PI0905369 A2 BRPI0905369 A2 BR PI0905369A2 BR PI0905369 A BRPI0905369 A BR PI0905369A BR PI0905369 A2 BRPI0905369 A2 BR PI0905369A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- compartmentalized kit
- pharmaceutical composition
- pharmaceutical
- compartmentalized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
- A61M5/281—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule
- A61M5/283—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule by telescoping of ampoules or carpules with the syringe body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08101682.6 | 2008-02-15 | ||
EP08101682A EP2090307A1 (en) | 2008-02-15 | 2008-02-15 | Pharmaceutical composition for the treatment or prevention of osteoarticular diseases |
EP08158285 | 2008-06-13 | ||
EP08158285.0 | 2008-06-13 | ||
PCT/EP2009/051739 WO2009101194A1 (en) | 2008-02-15 | 2009-02-13 | Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases |
Publications (5)
Publication Number | Publication Date |
---|---|
BRPI0905369A2 true BRPI0905369A2 (pt) | 2015-06-30 |
BRPI0905369B1 BRPI0905369B1 (pt) | 2019-04-24 |
BRPI0905369B8 BRPI0905369B8 (pt) | 2020-02-04 |
BRPI0905369C1 BRPI0905369C1 (pt) | 2020-11-17 |
BRPI0905369C8 BRPI0905369C8 (pt) | 2021-05-25 |
Family
ID=40550545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0905369A BRPI0905369C8 (pt) | 2008-02-15 | 2009-02-13 | composição farmacêutica, uso da composição farmacêutica e kit compartimentado |
Country Status (16)
Country | Link |
---|---|
US (3) | US20100285134A1 (pt) |
EP (1) | EP2252290B1 (pt) |
JP (2) | JP2011512345A (pt) |
KR (2) | KR101784642B1 (pt) |
CN (1) | CN101878029B (pt) |
AU (1) | AU2009214028B2 (pt) |
BR (1) | BRPI0905369C8 (pt) |
CA (1) | CA2703866C (pt) |
DK (1) | DK2252290T3 (pt) |
ES (1) | ES2658354T3 (pt) |
HK (1) | HK1149717A1 (pt) |
IL (1) | IL206080A (pt) |
NO (1) | NO2252290T3 (pt) |
PL (1) | PL2252290T3 (pt) |
PT (1) | PT2252290T (pt) |
WO (1) | WO2009101194A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2252290B1 (en) * | 2008-02-15 | 2017-11-29 | Bone Therapeutics S.A. | Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases |
ES2566551T3 (es) | 2009-07-16 | 2016-04-13 | Sunstar Inc. | Material que contiene proteoglucano |
US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
WO2012099216A1 (ja) | 2011-01-19 | 2012-07-26 | 国立大学法人弘前大学 | プロテオグリカンの大量調製法 |
WO2013076160A1 (en) | 2011-11-21 | 2013-05-30 | Université Libre de Bruxelles | Sustained release formulations useful in the treatment of diseases |
WO2013076162A1 (en) * | 2011-11-21 | 2013-05-30 | Université Libre de Bruxelles | Formulations useful in the treatment of osteoarticular diseases |
SG10201700525PA (en) * | 2012-07-25 | 2017-02-27 | Univ Hirosaki | Composition for preventing or treating osteoarthritis |
US10646574B2 (en) | 2014-07-21 | 2020-05-12 | Board Of Regents, The University Of Texas System | Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same |
CN105232453B (zh) * | 2015-10-30 | 2018-11-06 | 上海昊海生物科技股份有限公司 | 关节腔用地塞米松几丁糖纳米注射液及其制备方法 |
KR20240031326A (ko) | 2016-12-31 | 2024-03-07 | 바이오엑셀 테라퓨틱스 인코포레이티드 | 불안의 치료를 위한 설하 덱스메데토미딘의 용도 |
IT201700108102A1 (it) * | 2017-09-27 | 2019-03-27 | Univ Degli Studi Padova | Composizione di bactericidal/permeability increasing protein e acido ialuronico per il trattamento delle artropatie |
WO2019063320A1 (en) * | 2017-09-27 | 2019-04-04 | Universita' Degli Studi Di Padova | COMPOSITION COMPRISING A BACTERICIDE / PERMEABILITY INCREASING PROTEIN AND HYALURONIC ACID FOR THE TREATMENT OF ARTHROPATHIES |
CA3103431A1 (en) | 2018-06-27 | 2020-01-02 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
CA3145388A1 (en) | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
US11622949B1 (en) | 2022-08-04 | 2023-04-11 | Gad M. Gilad | Agmatine compositions for treatment of osteoarthritis |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5906934A (en) * | 1995-03-14 | 1999-05-25 | Morphogen Pharmaceuticals, Inc. | Mesenchymal stem cells for cartilage repair |
US5869041A (en) * | 1996-01-12 | 1999-02-09 | The Miriam Hospital | Delivery of bioactive compounds to an organism |
DE69705746T2 (de) * | 1996-12-20 | 2001-10-31 | Alza Corp | Injizierbare depotgelzubereitung und herstellungsverfahren |
IL129951A0 (en) * | 1997-07-02 | 2000-02-29 | Euro Celtique Sa | Prolonged anesthesia in joints and body spaces |
WO1999010385A1 (fr) * | 1997-08-22 | 1999-03-04 | Denki Kagaku Kogyo Kabushiki Kaisha | Gel d'acide hyaluronique, son procede de production et substance therapeutique le contenant |
WO2000017326A1 (en) | 1998-09-21 | 2000-03-30 | Musc Foundation For Research Development | Non-hematopoietic cells, including cardiomyocytes and skeletal muscle cells, derived from hematopoietic stem cells and methods of making and using them |
JP5090604B2 (ja) * | 2000-04-25 | 2012-12-05 | オシリス セラピューティクス,インコーポレイテッド | 動物の関節修復のための医薬組成物調製への間葉幹細胞の使用法 |
EP1365811A2 (en) * | 2000-07-14 | 2003-12-03 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
DE10053053A1 (de) * | 2000-10-19 | 2002-05-16 | Knoell Hans Forschung Ev | Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden |
WO2002089794A1 (en) * | 2001-05-07 | 2002-11-14 | Universite Catholique De Louvain | Method for treating neuropathic pain and pharmaceutical preparation therefor |
WO2003000190A2 (en) * | 2001-06-25 | 2003-01-03 | Depuy | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
US20070042951A1 (en) * | 2003-10-08 | 2007-02-22 | Allergan, Inc. | Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides |
EP1678149A2 (en) * | 2003-10-31 | 2006-07-12 | Neurogen Corporation | 4-amino(aza)quinoline derivatives as capsaicin receptor agonists |
WO2006039704A2 (en) | 2004-09-30 | 2006-04-13 | Janssen Pharmaceutica, N.V. | Pharmaceutical composition and method for treating a joint capsule arthropathy |
US20080275129A1 (en) * | 2005-03-04 | 2008-11-06 | Acure Pharma Ab | Methods and Pharmaceutical Compositions for the Treatment of Neurological Damage |
JP2009514969A (ja) * | 2005-11-09 | 2009-04-09 | コンビナトアールエックス インコーポレーティッド | 医学的状態を治療するための方法、組成物、およびキット |
ITPD20060219A1 (it) * | 2006-05-31 | 2007-12-01 | Fidia Farmaceutici | Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi |
EP2252290B1 (en) * | 2008-02-15 | 2017-11-29 | Bone Therapeutics S.A. | Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases |
-
2009
- 2009-02-13 EP EP09710250.3A patent/EP2252290B1/en active Active
- 2009-02-13 BR BRPI0905369A patent/BRPI0905369C8/pt active IP Right Grant
- 2009-02-13 ES ES09710250.3T patent/ES2658354T3/es active Active
- 2009-02-13 KR KR1020167013799A patent/KR101784642B1/ko active IP Right Grant
- 2009-02-13 PT PT97102503T patent/PT2252290T/pt unknown
- 2009-02-13 CN CN2009801011744A patent/CN101878029B/zh active Active
- 2009-02-13 WO PCT/EP2009/051739 patent/WO2009101194A1/en active Application Filing
- 2009-02-13 US US12/811,665 patent/US20100285134A1/en not_active Abandoned
- 2009-02-13 JP JP2010546354A patent/JP2011512345A/ja active Pending
- 2009-02-13 PL PL09710250T patent/PL2252290T3/pl unknown
- 2009-02-13 NO NO09710250A patent/NO2252290T3/no unknown
- 2009-02-13 AU AU2009214028A patent/AU2009214028B2/en active Active
- 2009-02-13 CA CA2703866A patent/CA2703866C/en active Active
- 2009-02-13 KR KR1020107011867A patent/KR101669682B1/ko active IP Right Grant
- 2009-02-13 DK DK09710250.3T patent/DK2252290T3/en active
-
2010
- 2010-05-30 IL IL206080A patent/IL206080A/en active IP Right Grant
-
2011
- 2011-04-20 HK HK11104036.5A patent/HK1149717A1/xx unknown
-
2012
- 2012-09-24 US US13/625,601 patent/US9446065B2/en active Active
-
2016
- 2016-08-22 JP JP2016161747A patent/JP6352995B2/ja active Active
- 2016-09-19 US US15/269,216 patent/US9872876B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2658354T3 (es) | 2018-03-09 |
JP6352995B2 (ja) | 2018-07-04 |
JP2011512345A (ja) | 2011-04-21 |
US9446065B2 (en) | 2016-09-20 |
EP2252290A1 (en) | 2010-11-24 |
KR101669682B1 (ko) | 2016-10-27 |
IL206080A0 (en) | 2010-11-30 |
CA2703866C (en) | 2016-11-29 |
PL2252290T3 (pl) | 2018-06-29 |
CN101878029A (zh) | 2010-11-03 |
BRPI0905369B1 (pt) | 2019-04-24 |
AU2009214028B2 (en) | 2014-06-12 |
KR20100134548A (ko) | 2010-12-23 |
KR20160065988A (ko) | 2016-06-09 |
US20100285134A1 (en) | 2010-11-11 |
US9872876B2 (en) | 2018-01-23 |
PT2252290T (pt) | 2018-02-14 |
EP2252290B1 (en) | 2017-11-29 |
BRPI0905369C8 (pt) | 2021-05-25 |
WO2009101194A1 (en) | 2009-08-20 |
BRPI0905369B8 (pt) | 2020-02-04 |
NO2252290T3 (pt) | 2018-04-28 |
IL206080A (en) | 2016-11-30 |
HK1149717A1 (en) | 2011-10-14 |
JP2016196510A (ja) | 2016-11-24 |
DK2252290T3 (en) | 2018-03-05 |
CA2703866A1 (en) | 2009-08-20 |
US20130084268A1 (en) | 2013-04-04 |
AU2009214028A1 (en) | 2009-08-20 |
KR101784642B1 (ko) | 2017-10-11 |
CN101878029B (zh) | 2013-04-03 |
US20170056434A1 (en) | 2017-03-02 |
BRPI0905369C1 (pt) | 2020-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2018005I1 (lt) | Farmacinė kompozicija | |
BRPI0905369A2 (pt) | Composição farmacêutica, composição e kit compartimentado | |
BRPI0906962A2 (pt) | Composto, e, composição farmacêutica | |
BRPI0906556A2 (pt) | Composto, e, composição farmacêutica | |
BRPI1010768A2 (pt) | composto, e, composição farmacêutica. | |
BRPI0721651A2 (pt) | Composição farmacêutica | |
BRPI0906749A2 (pt) | Composição | |
BRPI0913808A2 (pt) | composição | |
BRPI1011423A2 (pt) | composição injetável, kit e método cosmético. | |
BRPI0813775A2 (pt) | Composição | |
IT1392101B1 (it) | Composizione comprendente isoflavoni | |
ATE528048T1 (de) | Schweisshemmende/desodorierende zusammensetzung | |
BRPI0917681A2 (pt) | Composto, e, composição farmacêutica | |
BRPI0917231A2 (pt) | composição | |
BRPI0905715A2 (pt) | Composição farmacêutica e kit de componentes | |
DK2120884T3 (da) | Farmaceutisk sammensætning | |
DK2254873T3 (da) | Benzodiazepinforbindelse og farmaceutisk sammensætning. | |
DK2285413T3 (da) | Farmaceutisk sammensætning | |
BRPI0810557A2 (pt) | composição | |
BRPI0811274A2 (pt) | Composição | |
BRPI0921313A2 (pt) | composição farmaucêutica | |
BRPI0912118A2 (pt) | composto, composição farmacêutica, e, intermediário sintético | |
BRPI0811002A2 (pt) | Composição biofertilizante | |
BRPI0914182A2 (pt) | composto, e, composição farmacêutica | |
BRPI0912171A2 (pt) | composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2520 DE 25/04/2019 QUANTO AOS INVENTORES. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2520 DE 24/04/2020 QUANTO A DATA DE VALIDADE. |
|
B25G | Requested change of headquarter approved |
Owner name: BONE THERAPEUTICS (BE) |
|
B25A | Requested transfer of rights approved |
Owner name: BONE THERAPEUTICS (BE) ; GLOB-CO SRL (BE) |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/02/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |